NASDAQ : CCNE

CNB Financial Corporation

$34.27 USD

-$0.88 (-2.5%)

Volume
170.18K
Average Volume
153.9K
Market Capitalization
$1.02B
P/E Ratio
12.11
Dividend Yield
2.16%
Price Target
$34.50
Year High
$35.24
Year Low
$21.63
Day High
Day Low
Payout Ratio
$0.30
Current Ratio
$0.67
Source Headline
CNB Financial Corporation Announces Quarterly Dividend for Series A Preferred Stock and Related Depositary Shares Distribution

CLEARFIELD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) (the "Corporation") has announced the declaration of a quarterly cash dividend of $0.4453125 per depositary share (Nasdaq: CCNEP), resulting from the Corporation's declaration of a quarterly cash dividend of $17.8125 per share on its Series A Preferred Stock.

globenewswire.com - 2026-07-14 16:05:00

HWBK vs. CCNE: Which Community Bank Stock Is the Better Buy?

Hawthorn Bancshares and CNB Financial ride on different growth and diversification drivers, but which looks more compelling now? Let's dive in.

zacks.com - 2026-07-14 14:00:39

CNB Financial (CCNE) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes?

zacks.com - 2026-07-10 12:46:13

Are You Looking for a Top Momentum Pick? Why CNB Financial (CCNE) is a Great Choice

Does CNB Financial (CCNE) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-06-18 13:00:34

Is the Options Market Predicting a Spike in CNB Financial Stock?

Investors need to pay close attention to CCNE stock based on the movements in the options market lately.

zacks.com - 2026-06-17 15:56:04

Why CNB Financial (CCNE) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes?

zacks.com - 2026-06-08 12:46:24

Why CNB Financial (CCNE) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes?

zacks.com - 2026-05-22 12:46:20

CNB (CCNE) Upgraded to Buy: What Does It Mean for the Stock?

CNB (CCNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-05-18 13:01:14

CNB Financial Corporation Announces Quarterly Dividend For Common Stock

CLEARFIELD, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) declared a quarterly cash dividend of $0.19 per share of common stock payable on June 15, 2026 to common stock shareholders of record as of June 1, 2026.

globenewswire.com - 2026-05-12 16:05:00

CNB Financial (CCNE) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes?

zacks.com - 2026-05-06 12:46:46

Is the Options Market Predicting a Spike in CNB Financial Stock?

Investors need to pay close attention to CCNE stock based on the movements in the options market lately.

zacks.com - 2026-05-05 15:40:18

CNB Financial (CCNE) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes?

zacks.com - 2026-04-20 12:46:26

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers  CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amplified solid tumors at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego, CA.

globenewswire.com - 2026-04-20 07:00:00

Get CCNE Insider Trade Alerts

CCNE Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$34.00

1 analysts

Last Year

$34.50

2 analysts

All Time

$34.50

2 analysts

CCNE Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-04-21 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2026-02-11 Stephens & Co. Maintain Overweight Overweight
2025-07-24 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2025-07-11 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2025-04-16 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2025-01-13 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2024-12-04 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2024-04-17 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2023-04-06 Keefe, Bruyette & Woods Maintain Market Perform Market Perform
2014-02-03 Boenning & Scattergood Upgrade Neutral Outperform